Stock Analysis of Immunovant Inc (IMVT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code IMVT
Close 25.39
Change -1.02 / 3.86 %
Volume 2766.22 K
Vol Change -2849.67 K / 50.74 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Immunovant Inc
PE (TTM)

-3547.31

Very Poor
Price / Book

2080.13

Very Poor
Price / Sales

0

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

3708.31 M

Enterprise Value

3072.95 M

ROA (TTM)

-53.43

Very Poor
ROE (TTM)

-58.64

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

22.93 %

-259336.00 K
Debt to Equity

0

Excellent
Altman Z Score

43.87

Excellent
Quick Ratio

0

Poor
Cash Ratio

0

Poor


Highs/Lows of Immunovant Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week28.95 12.30 % 0.513 % 31.8124.88529-May-2431-May-24
Two Week30.7 17.30 % 0.486 % 31.8124.88529-May-2431-May-24
One Month27.44 7.47 % 4.80 % 32.024.88515-May-2431-May-24
Three Month35.37 28.22 % 3.56 % 37.1524.88501-Mar-2431-May-24
Six Months39.13 35.11 % 15.54 % 45.5824.88509-Jan-2431-May-24
One year21.01 20.85 % 26.26 % 45.5818.161509-Jan-2407-Jul-23
Two year4.24 498.82 % 27.72 % 45.588.5709-Jan-2414-Oct-22


Technical View of Immunovant Inc
RSI

31.54

Neutral
MACD

-0.661

Mild Bearish
ADX

18.33

Bearish
Super Trend

30.62

Bearish
Williams %R

-92.90

Mild Bullish
CCI

-281.36

Mild Bullish


EMA 5

27.33

Strong Bearish
EMA 15

28.69

Neutral
EMA 50

30.13

Mild Bearish
EMA 100

31.56

Strong Bearish
SMA 100

33.16

Strong Bearish
SMA 200

33.00

Strong Bearish
SMA 5 / 20

27.75 / 29.41

Bearish
SMA 15 / 50

29.38 / 29.77

Mild Bearish
SMA 50 / 200

29.77 / 33.00

Strong Bearish




Charts of Immunovant Inc


Returns of Immunovant Inc with Peers
Period / StockIMVTPRGOCBAYSGRY
1 Week-12.30%-1.26%0.0308%8.70%
1 Mth-7.47%-15.71%0.901%10.62%
3 Mth-28.22%4.84%46.17%-11.05%
6mth-35.11%-9.62%122.47%-15.73%
1 Year20.85%-13.86%262.50%-26.36%
2 Year498.82%-30.93%911.84%-29.59%
5 Years--34.48%151.39%222.05%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Immunovant Inc with Peers
Ratio / StockIMVTPRGOCBAYSGRY
PE-3547.31-486.15-7450.4410297.00
P/B2080.130.7844797.26560.53
ROA-53.43-0.071-37.242.50
ROE-58.64-0.161-64.398.54
Debt To Equity00.8540.3741.40
Revenue0
% 		4654.00 M
4.55 % 		31016.00 K
0 % 		2715.00 M
6.92 %
Net Income-259336.00 K
22.93 % 		-4100.00 K
97.08 % 		-90101.00 K
15.00 % 		-34300.00 K
37.18 %


Technicals of Immunovant Inc with Peers
Technical / StockIMVTPRGOCBAYSGRY-
ADX18.3335.5869.2517.46
CMF-0.271-0.330-0.225-0.147
MFI28.9316.6579.2056.91
RSI31.5430.9980.9959.78
MACD Abv SignalFalseFalseFalseTrue
Price Above 50 MAFalseFalseTrueTrue-
Price Above 200 MAFalseFalseTrueFalse-


About : Immunovant Inc

Address : 320 West 37th Street, New York, NY, United States, 10018
Tel : (917) 580-3099
URL : https://immunovant.com
Code : IMVT, ISIN : US45258J1025, Exchange : NASDAQ, Country : USA
Fiscal Year End : March
IPO date : 21_Jun_2019
Employee Count : 164

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.


Note : All Data Generated at the End of Trading Hours (EOD Data)